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Inhibiting angiogenesis is an effective approach to cancer therapy, 
but  it  has  been  associated  with  cardiovascular  toxic  effects.  At 
times, adverse events such as hypertension and heart failure have 
led to treatment cessation and even life-threatening consequences 
(1–7). Cancer patients have often been excluded from studies of 
cardiovascular disease, and patients with clinically significant car-
diovascular disease have been excluded from studies of new cancer 
therapies.  Consequently,  the  capacity  for  determining  the  inci-
dence or prevalence of cardiovascular toxic effects of anticancer 
agents  and  to  determine  their  optimal  management  has  been 
limited. Oncologists and cardiovascular medicine specialists have 
increasingly recognized that the prevention and management of 
these toxic effects is important for these potentially life-sustaining 
anticancer  agents  to  benefit  the  greatest  possible  number  of 
patients (8–14).
The Investigational Drug Steering Committee of the National 
Cancer Institute (NCI) formed a Cardiovascular Toxicities Panel 
joining members of its Angiogenesis Task Force with experts in the 
management  of  hypertension  and  cardiovascular  toxic  effects  in 
cancer patients to generate consensus recommendations to optimize 
risk assessment, monitoring, and safe administration of new agents, 
despite the currently limited data specific to this medical problem. 
This Commentary has been written for oncologists and cancer re-
searchers and also for a general medical audience, including primary 
care physicians and cardiovascular medicine specialists. Given the 
limited data specific to management of cardiovascular toxic effects 
of vascular endothelial growth factor (VEGF) signaling pathway 
(VSP) inhibitors, this is not a guidelines document but rather a 
collection of principles to guide safer more expansive use of these 
drugs and recommendations for the individual treating physician 
(see Box 1 for a summary of the panel’s recommendations).
Hypertension: A Toxic Effect of VEGF 
Signaling Pathway Inhibitors
Angiogenesis  (the  generation  of  new  branches  of  blood  vessels 
from preexisting vessels) is a complex process of numerous mole-
cules and cells within tissues. Drugs can inhibit angiogenesis by 
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Hypertension is a mechanism-based toxic effect of drugs that inhibit the vascular endothelial growth factor signaling pathway 
(VSP). Substantial evidence exists for managing hypertension as a chronic condition, but there are few prospectively collected 
data on managing acute hypertension caused by VSP inhibitors. The Investigational Drug Steering Committee of the National 
Cancer Institute convened an interdisciplinary cardiovascular toxicities expert panel to evaluate this problem, to make recom-
mendations to the Cancer Therapy Evaluation Program on further study, and to structure an approach for safe management by 
treating physicians. The panel reviewed: the published literature on blood pressure (BP), hypertension, and specific VSP inhibi-
tors; abstracts from major meetings; shared experience with the development of VSP inhibitors; and established principles of 
hypertension care. The panel generated a consensus report including the recommendations on clinical concerns summarized 
here. To support the greatest possible number of patients to receive VSP inhibitors safely and effectively, the panel had four 
recommendations: 1) conduct and document a formal risk assessment for potential cardiovascular complications, 2) recognize 
that preexisting hypertension will be common in cancer patients and should be identified and addressed before initiation of VSP 
inhibitor therapy, 3) actively monitor BP throughout treatment with more frequent assessments during the first cycle of treat-
ment, and 4) manage BP with a goal of less than 140/90 mmHg for most patients (and to lower, prespecified goals in patients 
with specific preexisting cardiovascular risk factors). Proper agent selection, dosing, and scheduling of follow-up should enable 
maintaining VSP inhibition while avoiding the complications associated with excessive or prolonged elevation in BP.
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Box 1. Summary recommendations
1.   Conduct and document a formal risk assessment for potential cardiovascular complications before vascular endothelial growth 
factor signaling pathway (VSP) inhibitor treatment. The assessment should include standardized blood pressure measurements (two 
separate sessions are suggested) and thorough history and examination to assess specific cardiovascular risk factors, and directed 
laboratory studies as indicated. (Table 2 summarizes the risk factors.) The purpose of this evaluation is to guide the physician and 
patient in determining the appropriate intensity of monitoring and control of blood pressure elevations. This provides an important 
opportunity to address comorbidities that through more attentive management could help prolong the patient’s life and support 
more aggressive anticancer therapy.
2.   Recognize that preexisting hypertension will be common in cancer patients and should be identified and addressed before initi-
ation of VSP inhibitor therapy. Given the suspected importance of pretreatment intervention in the management of VSP inhibitor– 
induced blood pressure elevations, properly collected, objective, office measurements or more thorough evaluations for isolated 
office hypertension (also known as “white coat hypertension”) should guide the risk assessment rather than patient and/or phy-
sician speculation and dismissal.
3.   Actively monitor blood pressure throughout treatment with more frequent assessments during the first cycle of treatment. The 
first cycle is typically when the bulk of the blood pressure elevation is expected to occur and when most patients unexpectedly 
present with elevations warranting treatment even in the absence of preexisting cardiovascular risk factors.
4.   The goal for hypertension control in patients receiving VSP inhibitor therapy is a maximum blood pressure of 140/90 mmHg, and 
efforts to reach this goal should begin before initiation of VSP inhibitor therapy. The recommendation for a goal of maintaining 
blood pressure less than 140/90 mmHg is based on prudence and consistency with general guidelines. As per the risk stratification 
considerations, targets should be adjusted lower for patients with multiple preexisting risk factors for adverse consequences of 
high blood pressure. For example, for patients with diabetes and/or chronic kidney disease, a goal blood pressure of less than 
130/80 mmHg is the current public health recommendation.
5.   Manage  blood  pressure  elevations  aggressively  to  avoid  the  development  of  complications  associated  with  excessive/prolonged   
elevations. Management requires attention to proper agent selection, dosing, and scheduling of follow-up to ensure efficacy and to 
control adverse effects of the antihypertensive agent. The panel suggests that at any time, if the oncologist or responsible medical team 
member has any difficulty in helping the patient progress to the goal blood pressure of 140/90 mmHg, consultation with the local 
hypertension specialist (cardiologist, nephrologist, endocrinologist, or certified hypertension specialist) should be obtained promptly. 
many mechanisms. The term VSP inhibitor includes agents that 
within their typical therapeutic dose range block downstream sig-
naling of the soluble ligand, VEGF, and its primary cognate re-
ceptor on endothelial cells, VEGF receptor-2 (VEGFR2). VSP 
inhibitors constitute a subclass of angiogenesis inhibitors with four 
agents  approved  for  marketing  by  multiple  regulatory  bodies 
worldwide: bevacizumab (Avastin), sorafenib (Nexavar), sunitinib 
(Sutent), and pazopanib (Votrient).
VEGF binding VEGFR2 activates the receptor’s kinase func-
tion,  triggering  multiple  downstream  signaling  cascades.  These 
cascades  are  associated  with  different  VEGF  effects  including 
increased capillary permeability, production of nitric oxide (leading 
to vascular smooth muscle relaxation), endothelial cell proliferation, 
migration, and survival under stress. Bevacizumab is a monoclonal 
antibody that binds VEGF. It is currently approved in combination 
with  different  chemotherapeutic  regimens  for  the  treatment  of 
advanced breast, colorectal, and lung cancer, in combination with 
interferon alpha for kidney cancer, and for glioblastoma as a single 
agent. Sorafenib has been approved as a single agent in the treat-
ment of hepatocellular and renal cancer, whereas sunitinib has been 
approved as single agent therapy for the treatment of renal and 
gastrointestinal stromal tumors. Pazopanib was more recently ap-
proved as another acceptable agent for treatment of renal cell carci-
noma. In addition to blocking the kinase activity of VEGFR2, these 
small molecules also block kinases in tumor cells, cardiomyocytes, 
and other cells too. Several additional VSP inhibitors are in the later 
stages of clinical development, including aflibercept (VEGF Trap), 
axitinib (AG-013736), cediranib (AZD2171, Recentin), motesanib 
(AMG 706), and vandetanib (ZD6474, Zactima).
Blood pressure (BP) elevation is an effect common to all VSP 
inhibitors, with hypertension reported as an adverse event in every 
trial of these drugs (Table 1). BP regulation entails complex physi-
ology, and the detailed mechanisms by which VSP inhibitors elevate 
BP in humans remain undetermined. Some evidence suggests that 
two effects of VSP inhibition on the systemic vasculature contribute 
to  BP  elevation:  1)  increased  vascular  tone  because  of  decreased 
nitric  oxide  production  and  2)  increased  peripheral  resistance 
because of endothelial cell damage and dysfunction (24–27). Although 
there are limited data on which directly to base recommendations for 
effective  pretreatment  evaluation,  on-treatment  surveillance,  and 
management of hypertension throughout the VSP inhibitor treat-
ment course, it is important to address this increasingly common 
clinical  problem.  Hemorrhage,  thrombosis,  nephrotoxicity,  and 
cardiac toxic effects are also increasingly recognized adverse events 
of VSP inhibitors, but because BP elevations are more common and 
easier to address, this Commentary focuses on BP management.
Principles for BP Management in Patients 
Receiving VSP Inhibitor Therapy
Shared and Divergent Goals of BP Management in Patients 
With  Advanced  Solid  Tumors  vs  Cardiovascular  Disease 
Prevention
Effectively lowering BP reduces morbidity and mortality from con-
gestive heart failure, myocardial infarction, stroke, and renal insuffi-
ciency. Risk for death from these conditions is proportional to the 
level of BP (28). Effective control of chronic hypertension reduces the 
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11) (29), and so management has been typically approached as a public 
health problem (30–32). A public health solution requires a simple and 
easy clinical process. Several expert panels periodically review epide-
miological and clinical trial data to produce evidence-based guidelines 
consistent with health-care system and regional cultural concerns.
A simple algorithm that could be applied by a physician’s support 
staff would be popular, but data support complex patient-specific 
evaluations  and  decision  making.  The  European  Societies  of 
Cardiology and Hypertension (ESCH) (33) have described a predic-
tive algorithm for BP control goals based on cardiovascular risk fac-
tors and adverse cardiovascular outcomes (Figure 1). In contrast to 
the population for which these long-term mortality risk reduction 
Table 1. Incidence of any and clinically significant hypertension in clinical trials of vascular endothelial growth factor signaling pathway 
(VSP) inhibitors*
Agent
First author, year  
(reference)





of grade ≥ 3, %
Incidence of any  
grade hypertension in  
the comparator group, %
Aflibercept Tew, 2007 (15) 162 46 18 NA
Axitinib† Rugo, 2007 (16) 167 30 5 5
Bevacizumab‡ Hurwitz, 2004 (17) 790 22 11 8
Cediranib† Hirte, 2008 (18) 49 72 33 NA
Motesanib Sherman, 2008 (19) 93 56 25 NA
Pazopanib‡ Hutson, 2007 (20) 161 37 8 NA
Sorafenib† Escudier, 2007 (21) 902 17 4 2
Sunitinib† Motzer, 2007 (22) 735 24 8 1
Vandetanib Arnold, 2007 (23) 106 21 2 9
*  For each agent, one of the larger studies with that drug and the reported incidence of hypertension by the National Cancer Institute’s Common Terminology 
Criteria for Adverse Events (CTCAE) is listed. For some agents, data from a randomized placebo-controlled trial are not yet available. Note the differences in 
reported rates, and grades cannot be accurately compared across trials because of differing clinical setting and the CTCAE versions used, but in every trial with a 
comparator arm, the incidence of hypertension is higher with the addition of the VSP inhibitor. NA = not applicable (no untreated comparator group).
†  Based on CTCAE version 3.0 (grade 3 hypertension is defined as “requiring more than one drug or more intensive therapy than previously”).
‡  Based on CTCAE version 2.0 (grade 3 hypertension is defined as “requiring initiation or increase medication”).
concepts have been developed, the patients for whom VSP inhibitor 
therapy is currently indicated have metastatic disease and limited life 
expectancy. Some patients might receive VSP inhibitor therapy for 
only a few months, and so the goals of BP management in this setting 
differ from those of primary prevention of long-term risk for cardio-
vascular disease. Nevertheless, control of BP is important for patients 
receiving VSP inhibitor therapy for the following five reasons:
 
  1.    Serious adverse events have been associated with unmanaged hy-
pertension (1–3,5,34), and these could be prevented with control 
of BP before and early in the course of VSP inhibitor therapy.
  2.    These agents can cause dramatic increases in BP from pretreat-
ment measurements (as high as 29 mmHg systolic and 27 mmHg 
diastolic in one prospective clinical investigation) (35) during the 
first week of treatment (35,36), and currently, it cannot be pre-
dicted which patients will have this magnitude of BP elevation.
  3.    Although  minimalist  approaches  to  hypertension  for  patients 
with incurable disease might be favored in certain circumstances, 
management  of  comorbidities,  including  hypertension,  could 
improve overall survival. One large study (37) demonstrated that 
the burden of comorbidities, especially when unmanaged, affects 
cancer patient survival as much as stage at diagnosis.
  4.    As the indications for these agents expand to more chronic treat-
ment  courses,  curative,  and  perhaps  preventive  settings,  the 
goals of BP management then become similar to those for pri-
mary prevention of cardiovascular disease.
  5.    Active  control  of  hypertension  should  allow  patients  to   
tolerate the highest effective dose of VSP inhibitor therapy and 
benefit from the tumor growth control for the longest period, 
improving quality and length of life with VSP inhibitor therapy. 
Specific Guidance for Assessment, Monitoring, and 
Management of Hypertension Associated With VSP 
Inhibitor Therapy
Rating  Hypertension  to  Determine  Intervention.  In  the  past, 
treatment-related hypertension was seldom a concern in anticancer 
Figure  1.  Stratification  of  cardiovascular  risk  and  its  relationship  to 
blood pressure in adults. Reprinted with permission from Mancia et al. 
(33). OD = subclinical organ damage; SBP = systolic blood pressure; 
DBP = diastolic blood pressure, HT = hypertension; MS = metabolic 
syndrome;  CV  =  cardiovascular.  As  per  the  European  Societies  of 
Cardiology and Hypertension guidelines low, moderate, high, and very 
high added risk refer to 10-year risk of a CV fatal or nonfatal event rela-
tive  to  the  average  population  risk.  These  categories  are  associated 
with population and occupation-based cohorts and empiric methods of 
quantitative risk determination. Risk factors are boldfaced in Table 2. 
The dashed line indicates that the categorization of hypertension might 
be variable and dependent on total CV risk. For example, a patient with 
established  CV  or  renal  disease  might  have  normal  blood  pressure 
limits of 129/84 mmHg, whereas someone with no other risk factors 
could have 150/95 mmHg as a normal blood pressure limit to achieve 
the same degree of cardiovascular risk reduction.jnci.oxfordjournals.org    JNCI | Commentary 599
therapeutics (38). During the development of the VSP inhibitors, 
hypertension  surveillance,  rating,  and  structured  adverse  event 
reporting  to  the  NCI  were  through  the  standardized  Common 
Terminology  Criteria  for  Adverse  Events  (CTCAE)  (39).  This 
rating  system  categorizes  “any  unfavorable  symptom,  sign,  or 
disease (including an abnormal laboratory finding) associated with 
the use of a medical treatment or procedure that may or may not be 
considered related to or caused by the medical treatment or proce-
dure.” For example, “hypertension” is an adverse event term cate-
gorized under “Cardiovascular (General).” All adverse events are 
graded on a 5-point scale of general proportionality: 0 = no event, 
within normal limits; grade 1 = mild adverse event; 2 = moderate 
event; 3 = severe and undesirable; 4 = life threatening or disabling; 
and 5 = death. The document’s purpose is to unify safety reporting 
so that reviewers can identify therapeutics, doses, or patient groups 
associated with unusual risk for severe adverse events. Because of its 
common use among clinical investigators and most practicing on-
cologists’ familiarity with the grading concepts, the CTCAE is often 
referenced in many circumstances beyond its intended use. CTCAE 
rating scales were not intended or validated to be instruments for 
grading severity of events, but most retrospective analyses of clinical 
trials of VSP inhibitors rely on the CTCAE grades. These grades 
do not reflect any typical hypertension classification system and so 
drawing inferences to guide management is challenging. The new 
CTCAE version 4 Hypertension scale has been aligned with the US 
National High Blood Pressure Education Program categories to 
improve communication among oncologists, cardiovascular medi-
cine specialists, and primary care physicians.
For three decades, the Joint National Committee of the National 
Heart, Lung, and Blood Institute-sponsored National High Blood 
Pressure  Education  Program  (the  JNC)  has  reviewed  data  and 
developed recommendations for detection, evaluation, and treat-
ment of hypertension. The current classification categorizes BP for 
adults aged 18 years or older as normal (<120/80 mmHg), prehy-
pertension  (120–139/80–89  mmHg)  warranting  intervention  in 
patients  with  high  risk,  stage  I  hypertension  (140–159/90–99 
mmHg)  warranting  intervention,  and  stage  II  hypertension 
(≥160/100) warranting immediate attentive intervention to prevent 
acute symptoms. Other major organizations (32,33) have developed 
similar concepts, with different numerical classifications, to guide 
whether, when, and which intervention should begin.
The panel recognized that at this time, integrating into day-to-
day clinical practice, a specific approach to BP in patients receiving 
VSP  inhibitors  presents  logistical  challenges.  Oncologists  are 
uniquely skilled to address numerous matters with their patients 
but under increasing time constraints. For the busy oncology spe-
cialist in a team environment that includes general medicine and 
cardiovascular disease specialists, colleagues more experienced in 
these matters might play a major collaborative role. For commu-
nity practitioners, this process is a natural extension of good gen-
eral medical care, and we highlight when risk is at a level that 
might warrant skills of specialists in other fields.
Pretreatment Assessment of Patient’s Risk for Cardiovascular 
Complications.  Pretreatment risk assessment determines the like-
lihood  that  the  patient  will  tolerate  unexpected  cardiovascular 
stress from these drugs without morbidity. It is reasonable to apply 
this  concept  of  total  cardiovascular  risk  to  guide  the  intensity   
of  pre-VSP  inhibitor  therapy  evaluation  and  intervention,  and   
on-treatment surveillance and intervention. Therefore, this panel 
recommends:
 
  1.    Formal evaluation and documentation of a patient’s pretreat-
ment risk for cardiovascular complications before initiation of 
VSP inhibitor therapy. The purpose of this assessment is not to 
exclude  patients  from  potential  life-extending  VSP  inhibitor 
therapy but rather to provide a systematic means by which risk 
for potential complications of VSP inhibitor therapy might be 
addressed efficiently for each patient. Most adult cancer patients 
are likely to have essential rather than secondary hypertension, 
so the identification of reversible secondary causes of hyperten-
sion is not part of this evaluation.
  2.    The pretreatment assessment should entail repeated BP mea-
surements, a history and examination to assess specific risk fac-
tors listed in Table 2, and directed laboratory or instrument tests 
in Table 2 or in addition to these as clinically indicated. 
Considerations for Pretreatment Risk Assessment.  The initial 
measurement of BP is important and should be performed with an 
appropriately calibrated device in accord with published recom-
mendations (40), including a correctly sized cuff and having the 
patient rest 5 minutes in the seated position before initial measure-
ment (see Supplementary Appendix 1, available online). The mean 
Table 2. Risk factors for adverse consequences of high blood 
pressure (BP)*
Systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg
Diabetes mellitus
Established CV disease including any history of:
  Ischemic stroke, cerebral hemorrhage, or transient ischemic attack
  Myocardial infarction, angina, coronary revascularization, or heart  
    failure
  Peripheral artery disease
  Retinal hemorrhages or exudates and papilledema
Established or subclinical renal disease including:
  Microalbuminuria or proteinuria (>30 mg/24 h)
  Serum creatinine in men >1.5 mg/dL, women >1.4 mg/dL
  Calculated or estimated glomerular filtration rate <60 mL/min/1.73 m
2
Subclinical organ damage previously documented by:
  ECG or echocardiogram revealing left ventricular hypertrophy
  Carotid ultrasound study revealing wall thickening or plaque
Three or more of the following CV risk factors:
  Age (men >55 y, women >65 y)
  Cigarette smoking
  Dyslipidemia as measured by:
    Total cholesterol >190 mg/dL or
    Low-density lipoprotein cholesterol >130 mg/dL or
    High-density lipoprotein cholesterol (men <40 mg/dL;  
      women <46 mg/dL) or
    Triglyceride > 150 mg/dL
  Fasting plasma glucose >100 mg/dL
  Family history of premature CV disease (first-degree male relative  
    age <55 y or first-degree female relative <65 y)
  Abdominal obesity male waist circumference >40 in; female >35  
    in (in persons of East Asian ancestry: male waist circumference  
    >35 in and for women >31 in)
*  Adapted, with permission, from Mancia et al. (33). CV = cardiovascular.600   Commentary | JNCI  Vol. 102, Issue 9  |  May 5, 2010
of a minimum of two measurements collected at least 3 minutes 
apart should be used. The collection of these measurements on 
two separate clinic visits is typically used to diagnose hypertension 
in patients without cancer.
Identifying hypertension pretreatment means additional work 
for the patient, in terms of addressing a comorbid condition, and for 
the physician in assessment and management. Anecdotally, panel 
members noted a tendency for colleagues and patients to explain 
and  dismiss  high  readings  rather  than  address  them  objectively. 
Given the suspected importance of pretreatment intervention for 
VSP inhibitor–induced elevation in BP, properly collected office 
measurements  or  more  thorough  evaluations  for  isolated  office 
hypertension/“white coat hypertension” should guide the risk as-
sessment rather than patient or physician speculation and dismissal. 
Explanations for previously undiagnosed hypertension in advanced 
cancer patients include uncontrolled pain. Baseline measurements 
should  be  reassessed  after  better  pain  control  with  appropriate 
agents  is  achieved  because  nonsteroidal  anti-inflammatory  drugs 
can increase pressure, whereas narcotics and better pain control will 
lower pressure. Members of the panel noted that patients and phy-
sicians tended to take this diagnostic evaluation more seriously if, 
similar to preoperative clearance, the patient was referred to an 
existing primary care clinician or treating cardiovascular medicine 
specialist for the assessment.
The assessment should focus on establishing pretreatment car-
diovascular risk, including identification of subclinical organ damage 
and concomitant clinical conditions. The assessment is simplified 
by the system advocated by the ESCH and summarized in Table 2. 
The six boldfaced items each constitute a risk factor for complica-
tions of elevated BP. We recommend stratifying patients as low risk 
= zero factors, high risk = one factor, and higher risk of at least two 
factors. Cancer patients initially evaluated for VSP inhibitor therapy 
could be at high risk for complications from elevated BP (Table 2), 
and this will only be identified by thorough clinical assessment. In 
patients who have not had recent routine screening for cardiovascu-
lar diseases, this evaluation will entail several tests beyond the com-
plete  blood  count  and  metabolic  profile  typically  reviewed  for 
cytotoxic chemotherapy regimens. According to Table 2, for most 
advanced cancer patients, thorough risk assessment will include an 
electrocardiogram and measurements of serum cholesterol and tri-
glycerides and of fasting plasma glucose. In many patients, echocar-
diogram  or  carotid  ultrasound  studies  might  be  indicated  to 
determine risk accurately. Registrational studies of bevacizumab, 
sorafenib, and sunitinib excluded patients with recent (within 6–12 
months of treatment initiation) “cardiac events” or “clinically signif-
icant  cardiovascular  disease,”  including  myocardial  infarction, 
severe  or  unstable  angina,  coronary  or  peripheral  artery  bypass 
grafting, symptomatic congestive heart failure, cerebrovascular ac-
cident, or transient ischemic attack. The drug labels recommend 
that patients should be carefully monitored for toxic effects. All of 
these individuals would be considered to be in the higher added risk 
cohort. Any patients not meeting the above criteria but classified as 
having higher added risk should undergo similar evaluation of the 
risk–benefit ratio and the most attentive risk reduction maneuvers.
The Goal BP in Patients Receiving VSP Inhibitor Therapy Is 
Less Than 140/90 mmHg.  The primary goal in this setting is to 
prevent hypertension-related toxic effects. The recommendation 
for maintaining BP less than 140/90 mmHg is based on prudence 
and consistency with JNC guidelines. For some patients in the 
higher added risk cohort, targets should be adjusted lower. For 
example, for patients with diabetes and/or chronic kidney disease, 
a goal BP of less than 130/80 mmHg is the current public health 
recommendation.  For  the  high-  and  higher-risk  patients,  BP 
should be less than 140/90 mmHg before initiating VSP inhibitor 
therapy.  If  the  patient  reports  already  taking  antihypertensive 
therapy, adherence to the regimen should be verified. If the patient 
is  adherent  and  could  tolerate,  the  dose  should  be  titrated  to 
achieve the 140/90 mmHg goal. If the dose is already the max-
imum, a second agent should be added and titrated appropriately 
with no less than weekly follow-up. The pace at which antihyper-
tensive therapy is titrated is determined by the treating physician’s 
balancing risks for delaying anticancer therapy with the threat of 
cardiovascular complications in the setting of incompletely con-
trolled cardiovascular risks.
If the patient is not receiving antihypertensive therapy, begin it 
intending to titrate to reduce BP to goal. Often, VSP inhibitor 
therapy should be started shortly after the initial oncology evalua-
tion. Shorter-acting agents with close follow-up (as frequently as 
every  2–4  days)  might  achieve  the  goal  BP  quickly,  and  the 
patient’s BP could then be maintained with an equivalent dose of 
a longer-acting agent. If the BP goal is not achieved, it may not be 
necessary to delay starting VSP inhibitor therapy until antihyper-
tensive therapy is fully titrated, as long as the BP is below the level 
that is likely to be associated with acute complications. Before be-
ginning VSP inhibitor therapy, obtain objective evidence of im-
proving  BP  control  and  plan  to  continue  titration  of  the 
antihypertensive  agent  to  the  numerical  goal  as  VSP  inhibitor 
therapy begins. If there is any difficulty making progress toward 
achieving the goal BP of less than 140/90 mmHg, consultation 
with  the  local  hypertension  specialist  should  be  obtained 
promptly.
In medical oncology practice, hypertension will be common, 
but  detection  depends  on  the  thoroughness  of  surveillance.  In 
1999–2000,  the  most  recently  studied  period  of  the  National 
Health and Nutrition Examination Survey (NHANES), the prev-
alence of stage I hypertension in the entire US population was 
28.7%; it was 65.4% in those aged 60 years and older. Of those 
found to be hypertensive, 69% were aware they had hypertension, 
58.4% were receiving some medication to lower BP, and among 
those treated, 53% had their BP within the goal therapeutic range. 
NHANES is not based on cancer patients, and one might specu-
late that the cancer population has a lower prevalence of hyperten-
sion than the general population, but two small prospective studies 
of previously treated cancer patients with advanced solid tumors 
undergoing careful pretreatment BP assessment, mean age 56–59 
years, reported rates of hypertension before VSP inhibitor therapy 
of  28%  (35)  and  29%  (3),  which  are  similar  to  the  general 
population.
Monitoring  BP  During  VSP  Inhibitor  Therapy.  Current  NCI 
clinical trial protocols recommend monitoring BP weekly during 
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weeks for the duration of treatment. After the first cycle is com-
pleted and a stable BP has been achieved, depending on the level 
of risk for complications, the evaluation schedule might be more 
conveniently aligned with routine clinical evaluations or home BP 
monitoring.  Cohort  studies  of  sorafenib  (17)  and  sunitinib  (3) 
detected elevations in BP for the population during the first cycle 
of treatment. In more intensive studies using home BP (36) or 
ambulatory BP monitoring (35), initial elevations were detected 
during the first week of treatment. If untreated, BP may further 
increase to concerning levels for patients with predisposition for 
cardiovascular complications. Consequently, early detection and 
attentive management of BP elevations might prevent some of the 
severe complications of VSP inhibitor therapy. The easiest ap-
proaches for maintaining BP in these patients within a safe range 
are likely to be weekly office nursing visits or as has been imple-
mented  in  many  NCI-sponsored  trials,  home  BP  monitoring. 
Home monitoring entails a greater degree of patient education, 
provides the patient with an opportunity to participate actively in 
her or his care and therefore, for patients who can afford to pur-
chase  a  certified  upper  arm  cuff  device  (eg,  no  wrist  or  finger 
device has been certified for accuracy comparable to brachial cuff 
measurements),  might  be  the  preferred  method.  In  some  NCI 
trials, patients are provided with a BP diary, including instructions 
for accurate self-measurement, and numerical thresholds warrant-
ing  a  call  to  the  physician’s  office  for  further  instructions  (see 
Supplementary Appendix 2, available online). For asymptomatic 
elevations  in  BP,  treatment  can  be  initiated  by  telephone,  and 
evaluation for proper dosing and adverse effects of antihyperten-
sive therapy can be scheduled after steady-state levels of the anti-
hypertensive agent have been reached days later.
This guidance should be adjusted for younger patients who are 
clearly  normotensive  and  at  low  baseline  risk.  One  study  of 
ambulatory monitoring and sorafenib (35) found the magnitude of 
elevation in BP in normotensive individuals to be highly variable. 
Some patients had no elevation in BP, and others had increases in 
diastolic BP greater than 20 mmHg. These changes in BP warrant 
management but might ordinarily go unaddressed in younger nor-
motensive patients who are considered low risk for cardiovascular 
complications. In these patients, on-treatment BP measurements 
might be considered “normal” because they are not above 140/90 
mmHg, but elevations of this magnitude within a short time frame 
(days to weeks) can place these patients among those at highest risk 
for  hypertensive  complications.  A  consensus  recommendation 
from the panel for these patients is to focus on the magnitude of 
the change in BP rather than the crossing of a population-based 
threshold,  such  as  140/90  mmHg.  Antihypertensive  treatment 
should be initiated in any patient having an increase in diastolic BP 
of 20 mmHg and greater even if the absolute measurement is in the 
“normal” range. Keeping the diastolic increase within 20 mmHg of 
the baseline measurement should maintain a safe margin.
Finally, although bevacizumab is currently the most commonly 
prescribed  VSP  inhibitor,  there  are  no  published  prospectively 
collected  data  on  the  time  course  of  BP  elevation.  In  animal 
models,  various  strategies  for  disrupting  the  VSP  including 
VEGF-binding agents demonstrate similar effects on the normal 
vasculature  over  the  same  time  course  (41,42).  Consequently, 
despite  differences  in  the  pharmacokinetics  of  bevacizumab, 
sorafenib, and sunitinib, in the absence of data suggesting other-
wise, similar surveillance methods are appropriate.
Management  of  Treatment  Emergent  Hypertension.  Rather 
than  recommend  a  specific  algorithm  for  management  of  VSP 
inhibitor–induced hypertension, we recommend a general algo-
rithm  based  on  fundamental  principles  that  experienced  practi-
tioners of BP management should find easy to implement. Patients 
developing stage I hypertension (≥140/90 mmHg) or increases in 
diastolic BP of 20 mmHg and higher from baseline should initiate 
antihypertensive therapy, have current therapy titrated to better 
control,  or  have  another  agent  added.  Patients  frequently  fast 
before blood collection on the day of office visits. Patients should 
be instructed to take their BP medication even if fasting to ensure 
accurate representation of the treated BP on office visits.
Panel members have routinely used many classes of agents to 
treat VSP inhibitor–induced hypertension, including thiazide di-
uretics, beta blockers, dihydropyridine and non-dihydropyridine 
calcium channel antagonists, angiotensin-converting enzyme in-
hibitors,  and  angiotensin  receptor  antagonists.  Each  of  these 
classes of antihypertensive agents has successfully controlled VSP 
inhibitor–induced  hypertension  on  an  individual  patient  basis. 
Whether any one agent is superior to another in successful control 
rates remains to be determined.
Consider four matters in selecting an antihypertensive drug: 1) 
cancer and cancer therapeutics–specific cautions and contraindica-
tions  to  avoid  a  specific  agent,  2)  compelling  considerations  for 
preferring a specific agent in the general medical setting, 3) cautions 
and contraindications to avoid a specific agent in the general medical 
setting, and 4) time available to titrate to goal effect. Table 3 sum-
marizes various classes of agents and important considerations in 
selection of an agent for patients in this setting (see Supplementary 
Appendix 3, available online, for suggestions on pairing different 
classes  of  agents).  For  patients  who  need  to  start  VSP  inhibitor 
therapy or return to treatment after cessation, achieving the goal BP 
can be more urgent than management of chronic hypertension. Oral 
angiotensin-converting  enzyme  inhibitors  can  relatively  rapidly 
lower BP, whereas some dihydropyridine calcium channel antago-
nists, such as felodipine and amlodipine, typically take 3–5 days for 
BP lowering to be apparent. The treating clinician will avoid iatro-
genic complications that lead to disruption of the anticancer treat-
ment and that could harm the patient if these matters are considered 
before antihypertensive therapy is prescribed. It is useful to note that 
some members of the panel reported that VSP inhibitor–induced 
hypertension could typically be safely controlled with low doses of 
amlodipine combined with an angiotensin-converting enzyme in-
hibitor or angiotensin II receptor blocker.
Prescribing antihypertensive agents warrants awareness of their 
pharmacology so that adverse effects can be recognized and cor-
rected and so assessment of response to therapy can be properly 
scheduled (a list of agents is featured in Supplementary Appendix 4, 
available online). The goal is to avoid complications from acute hy-
pertension, and this goal is most likely to be achieved by attentive 
management at the earliest convincing sign of BP elevation above an 
acceptable threshold for the patient and the patient’s cardiovascular 
risk. Excessively aggressive BP lowering or inappropriate selection 
of  antihypertensive  agents  could  have  consequences  for  cancer 602   Commentary | JNCI  Vol. 102, Issue 9  |  May 5, 2010
Table 3. Cautions, contraindications, and compelling considerations for major classes of antihypertensive drugs*
Class of drug
Cancer-specific cautions  
or reasons to avoid
Basis for preferred  
selection
General cautions and 
contraindications
Angiotensin-converting  
  enzyme inhibitors
Coadministration/titration with renal  
  clearance–dependent agents  
  (eg, cisplatin and pemetrexed);  
  hyperkalemia
Left ventricular systolic  
  dysfunction; diabetic  
  nephropathy
Renovascular disease; peripheral  
  vascular disease; renal  
  impairment
Angiotensin II receptor  
  blockers
Coadministration/titration with renal  
  clearance–dependent agents  
  (eg, cisplatin and pemetrexed);  
  hyperkalemia
Intolerance of other agents,  
  especially ACE inhibitors; left  
  ventricular systolic dysfunction;  
  diabetic nephropathy
Renovascular disease; peripheral  
  vascular disease; renal  
  impairment
Beta blockers Asthenia; malaise; fatigue; QT  
  interval prolonging drugs
Angina; history of myocardial  
  infarction; anxiety
Bradycardia/heart block; diabetes  
  (risk for hypoglycemia); asthma/ 
  chronic obstructive pulmonary  
  disease (wheezing);  
  decompensated heart failure
Calcium channel blockers  
  (eg, dihydropyridines)
Lower extremity swelling Elderly patients; isolated systolic  
  hypertension
Preexisting edema; slow  
  onset of action
Thiazide diuretics Gout; hypercalcemia; hypokalemia;  
  young patients (age ≤45 y);  
  QT interval prolonging drugs
Elderly patients; isolated systolic  
  hypertension; secondary stroke  
  prevention; typically least  
  expensive
Gout; documented sulfa allergy
*  Adapted, with permission, from Mancia et al. (33). Diltiazem and verapamil are inhibitors of CYP3A4, an important enzyme in the metabolism of sunitinib and sorafenib. 
Although specific drug–drug interactions are undocumented, as general guidance, the other agent classes might be used with a greater potential safety margin.
patients that are as damaging as the cardiovascular complications of 
VSP inhibitors, and so physician competence and judgment are es-
sential for successful implementation of these recommendations.
Because BP elevation is a reversible mechanism-based effect of 
VSP inhibition, discontinuation or where appropriate, dose reduc-
tion of the VSP inhibitor can also be used to control VSP inhibi-
tor–induced hypertension. This approach can be more easily used 
with the kinase inhibitors, which are typically administered once or 
twice daily. Temporary cessation of kinase inhibitors can be useful 
when  hypertension  is  difficult  to  control,  when  patients  report 
symptoms of excess BP elevation (13), or when the BP elevation is 
one  of  a  constellation  of  multiple  drug-associated  toxic  effects. 
Kinase  inhibitor  therapy  should  be  reinstituted  at  the  same  or 
lower  dose  once  BP  control  and  titration  of  antihypertensive 
agents is achieved to increase the likelihood for tumor control. 
However, if BP elevation is the only toxic effect a patient experi-
ences, reasonable efforts (fully titrating at least two antihyperten-
sive medications and referral to the local hypertension specialist if 
a BP of 140/90 mmHg still is not achieved) should be made to 
maintain the patient at the highest tolerable dose.
For  bevacizumab  and  other  VSP  inhibitors  with  long  half-
lives, eg, aflibercept (VEGF-Trap), the drug effect is not readily 
withdrawn after treatment cessation and the effects of dose reduc-
tion are unknown, so stricter implementation of dose interruption 
and  management  with  antihypertensives  could  be  required.  In 
NCI-sponsored trials, it is usually recommended that the bevaci-
zumab dose be held for BP higher than 160 mmHg systolic or 100 
mmHg diastolic or any symptomatic hypertension at the time of 
treatment. If BP remains uncontrolled despite active management 
with antihypertensives during the withholding period (reinstate-
ment of bevacizumab treatment is delayed for >4 weeks), then 
discontinuation of bevacizumab should be considered. Notably, 
this general statement is dependent on the physician’s expertise in 
controlling BP. Therefore, any patient who has to have a dose   
of bevacizumab withheld for uncontrolled hypertension despite 
active intervention should be referred to the local hypertension 
specialist to achieve the BP goal before the scheduled time for the 
next cycle of bevacizumab.
To achieve the BP control goals, physicians should be mindful of 
other agents that could magnify the BP-elevating effects of the VSP 
inhibitors. Excessive alcohol consumption and some agents that are 
commonly prescribed by oncologists also elevate BP, including non-
steroidal anti-inflammatory drugs (including cyclooxygenase 2 inhib-
itors), adrenal steroid hormones, erythropoietin, oral contraceptive 
hormones, and sympathomimetics, such as methylphenidate. If any of 
these agents is indicated during the course of VSP inhibitor therapy, 
anticipate further BP elevation and either increase the antihyperten-
sive therapy or the frequency of BP measurements accordingly.
Finally,  VSP  inhibition–induced  BP  elevation  will  dissipate 
with discontinuation of VSP inhibition. For patients discontinuing 
VSP  inhibitor  therapy,  anticipate  the  need  to  discontinue  or 
reduce the dose of antihypertensive agents administered to control 
the BP elevation associated with the VSP inhibitor.
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